Skip to main content

Browse


Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Dec 31, 2019
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.Read More

Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction Apr 1, 2017 - Jul 31, 2021
Acronym is derived from : Global approach to lowering adverse cardiac outcomes through improving contractility in heart failure.
A phase III randomised placebo controlled clinical trial sponsored by Amgen Inc of omecamtiv mercabil, a study dru... Read More

SOLOIST: A Randomized, Double-Blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Effects of SOtagliLiflozin on Clinical Outcomes in HemOdynamIcally STable Patients with Type 2 Diabetes POST worsening Heart Failure. Aug 1, 2018 - Jan 31, 2021
A Randomized, Double-Blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Effects of SOtagliLiflozin on Clinical Outcomes in HemOdynamIcally STable Patients with Type 2 Diabetes POST worsening Heart Failure.

AZD9977: A Phase I, Open Label, Randomized, Parallel group, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of ≥40 and ≤70 mL/min/1.73m2 Feb 1, 2019 - Jan 31, 2020
A Phase I, Open Label, Randomized, Parallel group, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF
and eGFR in the range of ≥40 and ≤70 mL/min/1.73m...


;